Johnson & Johnson has announced European approval for eligible multiple myeloma patients or caregivers to self-administer DARZALEX® from the fifth dose onwards.
Gilead Sciences and Kite have announced the reimbursement of two CAR T-cell therapies in Ireland for eligible adult patients with certain relapsed or refractory blood cancers.
